디지털 당뇨병 관리 시장 예측(-2034년) : 제품, 디바이스 접속성, 당뇨병 유형, 유통 채널, 도입 형태, 최종사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Digital Diabetes Management Market is accounted for $8.2 billion in 2026 and is expected to reach $24.6 billion by 2034, growing at a CAGR of 14.7% during the forecast period. Digital Diabetes Management refers to an integrated ecosystem of connected devices, software platforms, and remote services that assist patients and clinicians in monitoring, managing, and optimizing diabetes care. These solutions encompass continuous glucose monitors, smart insulin pens, mobile applications, and AI-driven decision support tools that collectively enable real-time tracking of glucose levels and personalized treatment adjustments. By bridging patient-generated data with clinical workflows, these technologies reduce diabetes-related complications, lower hospitalizations, and empower individuals to take an active role in their own long-term metabolic health management.

Market Dynamics:

Driver:

Rising global prevalence of diabetes and chronic disease burden

The accelerating global burden of Type 2 diabetes is compelling healthcare systems to adopt scalable, technology-driven management solutions. As patient populations expand and clinical resources remain constrained, digital platforms offer a viable path to continuous care without proportionally increasing workforce costs. Connected devices transmit glucose readings in real time, enabling timely clinical interventions that prevent acute episodes. Payers are increasingly recognizing the downstream cost savings of preventing hospitalizations through proactive digital monitoring, fueling reimbursement support and accelerating widespread institutional adoption of these platforms across diverse healthcare settings.

Restraint:

Data privacy concerns and regulatory compliance challenges

Digital diabetes tools handle sensitive health data, creating significant compliance obligations under regulations such as HIPAA and GDPR. Vendors must invest heavily in cybersecurity infrastructure, data encryption, and audit mechanisms to satisfy regulatory requirements. Patients in certain demographics express hesitancy about sharing continuous biometric data with third-party platforms, limiting adoption. Additionally, the fragmented global regulatory landscape means that devices cleared in one jurisdiction may require lengthy additional approvals elsewhere, substantially increasing time-to-market and development costs for innovators seeking international scale.

Opportunity:

Expansion of remote patient monitoring reimbursement frameworks

Governments and commercial insurers across North America and Europe are progressively formalizing reimbursement pathways for remote patient monitoring in chronic disease management. This policy shift significantly lowers the financial barrier for both providers deploying and patients accessing digital diabetes solutions. Reimbursement certainty incentivizes investment in next-generation CGM systems and closed-loop insulin delivery platforms. Emerging markets, particularly across Southeast Asia, are also witnessing telehealth policy reforms, creating new addressable markets. Vendors that build strong clinical evidence for outcomes-based billing models stand to capture substantial contract value as payer frameworks mature.

Threat:

Interoperability gaps between devices and electronic health records

The persistent lack of seamless data exchange between digital diabetes devices and hospital electronic health record systems creates friction in clinical workflows, reducing the perceived value of connected solutions. When clinicians must manually reconcile patient-reported data with in-clinic measurements, time savings evaporate and trust in digital tools erodes. Proprietary data standards used by major device manufacturers further hinder third-party integration. Without universal interoperability protocols, healthcare institutions are reluctant to commit significant budget to platforms that cannot natively communicate with their existing infrastructure.

Covid-19 Impact:

The COVID-19 pandemic initially strained diabetes care delivery by limiting in-person clinic visits, but simultaneously validated the utility of remote monitoring. Hospitals rapidly expanded telehealth capabilities, normalizing virtual consultations for chronic disease management. Device manufacturers accelerated cloud connectivity features, while regulators issued emergency use authorizations for digital health tools. Post-pandemic, heightened awareness of chronic disease vulnerability has driven sustained investment in preventive digital care, positioning the market for durable long-term expansion despite early supply chain disruptions.

The Devices segment is expected to be the largest during the forecast period

The Devices segment is expected to account for the largest market share during the forecast period, driven by strong and ongoing demand for continuous glucose monitoring (CGM) systems and smart insulin pens. Hardware represents the essential physical touchpoint of the digital diabetes ecosystem, with CGM sensors commanding premium pricing and repeat consumable sales. Growing clinical guidelines endorsing CGM use across all diabetes types, combined with falling sensor costs, are steadily broadening the addressable patient base. Established device makers and emerging start-ups alike are investing in miniaturized, longer-wear sensors to sustain this segment's market leadership.

The AI-Based Decision Support Tools segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the xx segment is predicted to witness the highest growth rate. Machine learning algorithms trained on large longitudinal datasets are now capable of anticipating hyperglycemic and hypoglycemic events hours in advance, enabling truly preventive interventions. Integration with closed-loop insulin delivery systems further amplifies clinical value. Pharmaceutical companies and digital health firms are co-investing in algorithm validation studies to accelerate regulatory clearance, positioning AI decision support as the fastest-growing innovation frontier within the broader digital diabetes landscape.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the highest per-capita diabetes prevalence among developed economies and well-established reimbursement pathways for CGM devices. The United States leads adoption, supported by FDA-cleared device pipelines, a mature private insurance ecosystem, and clinical guidelines from the American Diabetes Association endorsing continuous monitoring. Strong venture capital activity in digital health, combined with hospital system mandates for chronic disease remote monitoring programs, provides a favorable environment for sustained revenue concentration in this region.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by a rapidly expanding diabetic population across China, India, and Southeast Asia. Rising urban incomes and expanding middle-class health consciousness are driving demand for convenient, connected self-management solutions. Governments in the region are investing heavily in digital health infrastructure, and local manufacturers are developing cost-competitive CGM devices tailored to regional affordability. The convergence of growing disease prevalence, improving internet connectivity, and evolving national reimbursement policies makes Asia Pacific the most dynamic growth frontier in global digital diabetes management.

Key players in the market

Some of the key players in Digital Diabetes Management Market include Abbott Laboratories, DexCom, Inc., Medtronic plc, Insulet Corporation, F. Hoffmann-La Roche Ltd., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Tandem Diabetes Care, Inc., B. Braun Melsungen AG, Sanofi S.A., Glooko, Inc., Senseonics Holdings, Inc., DarioHealth Corp., Ypsomed Holding AG, ARKRAY, Inc.

Key Developments:

In March 2026, Abbott Laboratories Abbott Laboratories announced the commercial launch of its next-generation FreeStyle Libre 4 continuous glucose monitoring sensor in key European markets, featuring an extended 15-day wear period and enhanced Bluetooth connectivity for seamless integration with third-party insulin delivery devices.

In January 2026, DexCom, Inc. DexCom entered into a strategic collaboration agreement with a leading pharmacy benefit manager to integrate its G7 CGM system into employer-sponsored diabetes prevention programs, aiming to expand access to real-time glucose monitoring for high-risk individuals across the United States.

Products Covered:

• Devices
• Software & Platforms
• Services

Device Connectivities Covered:

• Bluetooth Enabled
• NFC Enabled
• Wi-Fi Enabled
• Smartphone Integrated
• Cloud Connected

Diabetes Types Covered:

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Prediabetes

Distribution Channels Covered:

• Online Platforms
• Retail Pharmacies
• Hospital Pharmacies
• Direct-to-Consumer Channels

Deployment Modes Covered:

• Cloud-Based Solutions
• On-Premise Solutions
• Hybrid Solutions

End Users Covered:

• Hospitals & Clinics
• Homecare Settings
• Diagnostic Centers
• Academic & Research Institutes
• Patients/Individual Users
• Payers & Insurance Providers

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Diabetes Management Market, By Product

• 5.1 Devices
  • 5.1.1 Continuous Glucose Monitoring (CGM) Systems
  • 5.1.2 Smart Glucose Meters
  • 5.1.3 Insulin Pumps
  • 5.1.4 Smart Insulin Pens
  • 5.1.5 Wearable Diabetes Devices
• 5.2 Software & Platforms
  • 5.2.1 Mobile Applications
  • 5.2.2 Cloud-Based Data Management Platforms
  • 5.2.3 Diabetes Analytics Software
  • 5.2.4 AI-Based Decision Support Tools
• 5.3 Services
  • 5.3.1 Remote Monitoring Services
  • 5.3.2 Digital Coaching Services
  • 5.3.3 Telemedicine Services
  • 5.3.4 Subscription-Based Diabetes Management Programs

6 Global Digital Diabetes Management Market, By Device Connectivity

• 6.1 Bluetooth Enabled Devices
• 6.2 NFC Enabled Devices
• 6.3 Wi-Fi Enabled Devices
• 6.4 Smartphone Integrated Devices
• 6.5 Cloud Connected Systems

7 Global Digital Diabetes Management Market, By Diabetes Type

• 7.1 Type 1 Diabetes
• 7.2 Type 2 Diabetes
• 7.3 Gestational Diabetes
• 7.4 Prediabetes

8 Global Digital Diabetes Management Market, By Distribution Channel

• 8.1 Online Platforms
• 8.2 Retail Pharmacies
• 8.3 Hospital Pharmacies
• 8.4 Direct-to-Consumer Channels

9 Global Digital Diabetes Management Market, By Deployment Mode

• 9.1 Cloud-Based Solutions
• 9.2 On-Premise Solutions
• 9.3 Hybrid Solutions

10 Global Digital Diabetes Management Market, By End User

• 10.1 Hospitals & Clinics
• 10.2 Homecare Settings
• 10.3 Diagnostic Centers
• 10.4 Academic & Research Institutes
• 10.5 Patients/Individual Users
• 10.6 Payers & Insurance Providers

11 Global Digital Diabetes Management Market, By Geography

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
  • 11.1.3 Mexico
• 11.2 Europe
  • 11.2.1 United Kingdom
  • 11.2.2 Germany
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Netherlands
  • 11.2.7 Belgium
  • 11.2.8 Sweden
  • 11.2.9 Switzerland
  • 11.2.10 Poland
  • 11.2.11 Rest of Europe
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Indonesia
  • 11.3.7 Thailand
  • 11.3.8 Malaysia
  • 11.3.9 Singapore
  • 11.3.10 Vietnam
  • 11.3.11 Rest of Asia Pacific
• 11.4 South America
  • 11.4.1 Brazil
  • 11.4.2 Argentina
  • 11.4.3 Colombia
  • 11.4.4 Chile
  • 11.4.5 Peru
  • 11.4.6 Rest of South America
• 11.5 Rest of the World (RoW)
  • 11.5.1 Middle East
    • 11.5.1.1 Saudi Arabia
    • 11.5.1.2 United Arab Emirates
    • 11.5.1.3 Qatar
    • 11.5.1.4 Israel
    • 11.5.1.5 Rest of Middle East
  • 11.5.2 Africa
    • 11.5.2.1 South Africa
    • 11.5.2.2 Egypt
    • 11.5.2.3 Morocco
    • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

• 12.1 Industry Value Network and Supply Chain Assessment
• 12.2 White-Space and Opportunity Mapping
• 12.3 Product Evolution and Market Life Cycle Analysis
• 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

• 13.1 Mergers and Acquisitions
• 13.2 Partnerships, Alliances, and Joint Ventures
• 13.3 New Product Launches and Certifications
• 13.4 Capacity Expansion and Investments
• 13.5 Other Strategic Initiatives

14 Company Profiles

• 14.1 Abbott Laboratories
• 14.2 DexCom, Inc.
• 14.3 Medtronic plc
• 14.4 Insulet Corporation
• 14.5 F. Hoffmann-La Roche Ltd.
• 14.6 Ascensia Diabetes Care Holdings AG
• 14.7 LifeScan, Inc.
• 14.8 Tandem Diabetes Care, Inc.
• 14.9 B. Braun Melsungen AG
• 14.10 Sanofi S.A.
• 14.11 Glooko, Inc.
• 14.12 Senseonics Holdings, Inc.
• 14.13 DarioHealth Corp.
• 14.14 Ypsomed Holding AG
• 14.15 ARKRAY, Inc.